ATE510538T1 - Zusammensetzungen und verfahren für nervenschutz - Google Patents

Zusammensetzungen und verfahren für nervenschutz

Info

Publication number
ATE510538T1
ATE510538T1 AT07836818T AT07836818T ATE510538T1 AT E510538 T1 ATE510538 T1 AT E510538T1 AT 07836818 T AT07836818 T AT 07836818T AT 07836818 T AT07836818 T AT 07836818T AT E510538 T1 ATE510538 T1 AT E510538T1
Authority
AT
Austria
Prior art keywords
methods
compositions
disclosed
compounds
nerve protection
Prior art date
Application number
AT07836818T
Other languages
English (en)
Inventor
Joseph Steiner
Avindra Nath
Norman Haughey
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE510538T1 publication Critical patent/ATE510538T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
AT07836818T 2006-08-11 2007-08-13 Zusammensetzungen und verfahren für nervenschutz ATE510538T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83736506P 2006-08-11 2006-08-11
PCT/US2007/018001 WO2008021368A2 (en) 2006-08-11 2007-08-13 Compositions and methods for neuroprotection

Publications (1)

Publication Number Publication Date
ATE510538T1 true ATE510538T1 (de) 2011-06-15

Family

ID=39082698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07836818T ATE510538T1 (de) 2006-08-11 2007-08-13 Zusammensetzungen und verfahren für nervenschutz

Country Status (4)

Country Link
US (2) US20080090897A1 (de)
EP (1) EP2056818B1 (de)
AT (1) ATE510538T1 (de)
WO (1) WO2008021368A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058269A2 (en) * 2006-11-09 2008-05-15 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
US8383865B2 (en) * 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
EP2749552B1 (de) * 2007-04-17 2015-11-18 Codman & Shurtleff, Inc. Curcumin-Resveratrol-Hybride
EP2164865A2 (de) * 2007-06-13 2010-03-24 Hochschule Mannheim Verbindungen zur modulation der huntington-aggregation, verfahren und mittel zur identifizierung solcher verbindungen
JP5453693B2 (ja) * 2007-10-29 2014-03-26 ディーエスエム アイピー アセッツ ビー．ブイ． レスベラトロルおよびペクチンを含有する組成物
US7745670B2 (en) * 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
US8969417B2 (en) 2008-06-06 2015-03-03 Pharmatwob Ltd. Pharmaceutical compositions for treatment of Parkinsons disease
US7985776B2 (en) 2008-06-27 2011-07-26 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
WO2010014613A2 (en) * 2008-07-28 2010-02-04 Emory University Treating various disorders using trkb agonists
EP2373999A4 (de) * 2008-12-09 2012-11-07 Stephanie Fryar-Williams Neue biomarker
US7723515B1 (en) * 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
US20100286585A1 (en) * 2009-01-26 2010-11-11 Codman & Shurtleff, Inc. Shunt Delivery of Curcumin
US9545117B2 (en) * 2009-02-03 2017-01-17 Tropicana Products, Inc. Microencapsulated citrus phytochemicals and application to beverages
US20100196554A1 (en) * 2009-02-03 2010-08-05 Tropicana Products, Inc. Microencapsulated citrus phytochemicals comprising citrus limonoids and application to beverages
US20100196577A1 (en) * 2009-02-03 2010-08-05 Tropicana Products, Inc. Microencapsulated citrus phytochemicals comprising citrus limonoids and application to sports drinks
US20100196549A1 (en) * 2009-02-03 2010-08-05 Tropicana Products, Inc. Microencapsulated citrus phytochemicals and application to sports drinks
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
CA2764038A1 (en) * 2009-05-29 2010-12-02 The Trustees Of Columiba University In The City Of New York Modulation of phospholipase d for the treatment of neurodegenerative disorders
JP2012530701A (ja) * 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症のラキニモドでの治療
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
CA2791711A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
CN101849541A (zh) * 2010-05-26 2010-10-06 中国科学院南海海洋研究所 一种柠檬苦素化合物-凯雅馨作为椰心叶甲毒杀剂的应用
CN101849542A (zh) * 2010-06-03 2010-10-06 中国科学院南海海洋研究所 木果楝柠檬苦素a作为椰心叶甲毒杀剂的应用
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
US20130225694A1 (en) * 2012-02-24 2013-08-29 Oklahoma Medical Research Foundation Compositions and methods of inhibiting retinal degeneration
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
EP3116554A4 (de) * 2014-03-14 2017-08-23 Teva Pharmaceutical Industries Ltd. Transmukosale verabreichung von laquinimod durch orale pflaster
US10493122B2 (en) * 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
EP3193870A4 (de) * 2014-09-16 2018-04-25 Teva Pharmaceutical Industries Ltd. Behandlung von neurodegenerativen erkrankungen mit einer kombination aus laquinimod und fingolimod
WO2016122832A1 (en) * 2015-01-30 2016-08-04 Natural Formulations Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries
CN111939163A (zh) * 2019-05-16 2020-11-17 复旦大学 葛杜宁在制备预防和治疗亨廷顿病药物中的用途
FR3114241A1 (fr) * 2020-09-18 2022-03-25 C F E B Sisley Compositions cosmétiques amincissantes contenant un ou plusieurs limonoïdes
CN113855686A (zh) * 2021-11-22 2021-12-31 西北农林科技大学 柠檬苦素在制备抗癫痫产品中的应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
JP2616252B2 (ja) 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
WO1995022963A1 (en) 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Drug targeting system, method for preparing same and its use
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
CA2295177C (en) 1997-06-13 2007-01-09 Medinova Medical Consulting Gmbh Drug targeting system, method of its preparation and its use
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20020006953A1 (en) 1999-11-05 2002-01-17 Carla R. McGill Modification of cholesterol concentrations with citus phytochemicals
AU2001232182A1 (en) 2001-01-15 2002-07-24 Kgk Synergize Compositions and methods for regulating lipoproteins and hypercholesterolmia with limonoids flavonoids and tocotrienols
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
EP2164865A2 (de) * 2007-06-13 2010-03-24 Hochschule Mannheim Verbindungen zur modulation der huntington-aggregation, verfahren und mittel zur identifizierung solcher verbindungen
WO2009020601A2 (en) * 2007-08-03 2009-02-12 Cornell University Atf4 inhibitors and their use for neural protection, repair, regeneration, and plasticity

Also Published As

Publication number Publication date
EP2056818B1 (de) 2011-05-25
US9289412B2 (en) 2016-03-22
US20080090897A1 (en) 2008-04-17
WO2008021368A2 (en) 2008-02-21
EP2056818A2 (de) 2009-05-13
US20100056617A1 (en) 2010-03-04
EP2056818A4 (de) 2009-09-23
WO2008021368A3 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
CL2007002513A1 (es) Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
PH12015501737B1 (en) Androgen receptor modulators and uses thereof
IN2012DN02177A (de)
IN2012DN02702A (de)
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
IN2012DN00971A (de)
MX2009007345A (es) Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2007092065A3 (en) Compounds and compositions as lxr modulators
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties